Clinical Trial of Tesamorelin to Reduce Liver Fat in People With HIV

Clinical Trial of Tesamorelin to Reduce Liver Fat in People With HIV

Non-alcoholic fatty liver disease, or NAFLD, is a common health problem in people with HIV that can lead to liver damage. NIAID researchers in Bethesda, Maryland, are testing the effectiveness of the growth hormone tesamorelin in reducing liver fat in people with HIV.

Key inclusion criteria include:

• Men and women ages 18 to 65 years of age
• HIV-infection and treatment with stable antiretroviral regimen for more than six months
• Known or suspected non-alcoholic fatty liver disease

Read more about the clinical trial of Tesamorelin Effects on Liver Fat and Histology in HIV (study ID NCT02196831) www.clinicaltrials.gov/ct2/show/NCT02196831 .